<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02051621</url>
  </required_header>
  <id_info>
    <org_study_id>A201070</org_study_id>
    <nct_id>NCT02051621</nct_id>
  </id_info>
  <brief_title>Therapy of Atrial Flutter by Afib Ablation</brief_title>
  <acronym>TripleA</acronym>
  <official_title>Isolated Atrial Fibrillation Ablation in Patients With Isolated Atrial Flutter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rostock</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ablation of the cavotricuspid isthmus (CTI) in the right atrium is currently the therapy of
      choice for the treatment of typical atrial flutter (3,4). It is a curative approach and has a
      high success rate (5). It has been recognized that patients with typical atrial flutter often
      complain of atrial fibrillation (1,2). Current clinical and experimental studies confirm the
      close relationship between atrial flutter (AFL) and atrial fibrillation (AF) and raise a
      question, if both arrhythmias are different forms of a common electrical phenomenon with
      atrial fibrillation being the underlying clinical problem (6).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current clinical and experimental studies confirm the close relationship between atrial
      flutter (AFlut) and atrial fibrillation (Afib). After initiation of Afib this may organize
      under special intrinsic conditions or due to antiarrhythmic medication to AFlut so Afib may
      be supposed the underlying arrhythmia. Therefore after successful ablation of AFlut this
      reentrant circuit is not longer possible and Afib persists. After new occurrence of Afib a
      long diagnostic and therapeutic marathon begins with AF ablation at the end of all
      therapeutic efforts. This double burden for the patient and the health system can probably be
      avoided by directly and effectively treating the underlying arrhythmia AF.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number or patients with a recurrence of any atrial arrhythmia</measure>
    <time_frame>2 years</time_frame>
    <description>Number (percentage) of patients with any atrial arrhythmia lasting longer than 30 s after ablation assessed by implantable loop recorder or 7-day-holter-ECG: AFL after AF ablation compared to the AFL ablation group and AF in both ablation groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with atrial flutter recurrence</measure>
    <time_frame>2 years</time_frame>
    <description>Number (percentage) of patients with any AFL episode after ablation or under medical therapy assessed by implantable loop recorder or 7-day-holter-ECG, compared between all 3 interventions (medical treatment vs. AFL Ablation vs. AF ablation)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <arm_group>
    <arm_group_label>Cavo-tricuspid-isthmus-ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ablation of atrial flutter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary vein isolation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pulmonary vein isolation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiarrhythmic drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medical treatment of atrial flutter with either class I antiarrhythmics (flecainide (Tambocor ®) 100 mg twice daily or propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily
cardioversion as needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiarrhythmic drug</intervention_name>
    <description>medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed</description>
    <arm_group_label>Antiarrhythmic drug</arm_group_label>
    <other_name>medical treatment of atrial flutter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cavo-tricuspid-isthmus-ablation</intervention_name>
    <description>irrigated radiofrequency (RF)-ablation of the cavo-tricuspid-isthmus catheter used: Thermocool R (F-type), Biosense Webster, Diamond Bar, CA, USA</description>
    <arm_group_label>Cavo-tricuspid-isthmus-ablation</arm_group_label>
    <other_name>Ablation of atrial flutter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary vein isolation</intervention_name>
    <description>pulmonary vein angiography followed by antral pulmonary vein isolation using 3D-electroanatomical Mapping mapping system: Carto 3 (Biosense Webster, Diamond Bar, CA, USA) catheter used for irrigated RF-ablation: Navistar Thermocool R (D, E or F-type according to atrial dimensions), Biosense Webster, Diamond Bar, CA, USA</description>
    <arm_group_label>Pulmonary vein isolation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with- in 12-Channel-ECG documented atrial tachycardia suggestive of typical
             isthmus dependent atrial flutter

          -  &gt; 21 years

        Exclusion Criteria:

          -  - AFL as secondary to an accessory pathway

          -  Antiarrhythmic treatment for AF

          -  AF

          -  Previous AF ablation

          -  Dilatation of left atrium &gt; 6 cm

          -  Cardiac surgery less &lt; 3 weeks

          -  Congenital heart disease

          -  Cardiac ischemia or coronary artery disease that needs intervention

          -  Life expectancy less than 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dietmar Baensch, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralph Schneider, MD</last_name>
    <email>ralph.schneider@med.uni-rostock.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dietmar Baensch, PhD, MD</last_name>
    <email>diemar.baensch@med.uni-rostock.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitiy Medical Centre Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietmar Baensch, PhD, MD</last_name>
      <email>dietmar.baensch@med.uni-rostock.de</email>
    </contact>
    <investigator>
      <last_name>Ralph Schneider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joerg Lauschke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolfgang Voss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cindy Schneider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>January 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <last_update_submitted>January 30, 2014</last_update_submitted>
  <last_update_submitted_qc>January 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rostock</investigator_affiliation>
    <investigator_full_name>Dietmar Baensch</investigator_full_name>
    <investigator_title>Professor Dr. med.</investigator_title>
  </responsible_party>
  <keyword>pulmonary vein isolation</keyword>
  <keyword>isthmus ablation</keyword>
  <keyword>recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

